Nektar Therapeutics
NKTR
177 hedge funds and large institutions have $1.91B invested in Nektar Therapeutics in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 66 increasing their positions, 63 reducing their positions, and 18 closing their positions.
24% more call options, than puts
Call options by funds: $3.22M | Put options by funds: $2.6M
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
5% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 63
1% more capital invested
Capital invested by funds: $1.9B → $1.91B (+$15.1M)
1% more funds holding
Funds holding: 176 → 177 (+1)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$18.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.49M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.55M |
| 4 |
PC
PointState Capital
New York
|
+$2.98M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$26.8M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$26.4M |
| 3 |
AG
Artal Group
Luxembourg
|
-$8.94M |
| 4 |
D.E. Shaw & Co
New York
|
-$8.59M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$4.26M |
NKTR Hedge Fund Activity: Q2 2016 in Review
177 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2016, worth a combined $1.91B — up 0.79% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NKTR positions and 18 closed out — a net gain of 2 holders — while 66 added to existing stakes and 63 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $18.1M. The largest seller was Millennium Management, cutting an estimated $26.8M.
- 177 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2016, up from 176 in Q1 2016.
- Funds reported $1.91B of Nektar Therapeutics stock for Q2 2016, up 0.79% quarter-over-quarter.
- 20 funds opened new Nektar Therapeutics positions in Q2 2016 and 18 closed out, a net change of +2 holders.
- The largest Nektar Therapeutics buyer in Q2 2016 was Westfield Capital Management, an estimated $18.1M added.
- The largest Nektar Therapeutics seller in Q2 2016 was Millennium Management, an estimated $26.8M sold.
Based on aggregated 13F filings for Q2 2016.